Zepbound Prior Authorization: Criteria, Common Denials, and How to Get Approved

Your prescriber sends the Zepbound prescription, and the pharmacy says it needs prior authorization. That means your plan will pay only after it reviews the request and agrees you meet its criteria. For Zepbound, the review turns on two things: which FDA-approved use the prescription is for, and whether the paperwork proves you meet the plan's rules for that use.

This guide covers what those criteria usually look like, why the sleep apnea use changed coverage for some people, the most common reasons for denial, and what renewals require. If you have already been denied, the full appeal process is in our GLP-1 prior authorization appeal guide. For prices, see how much Zepbound costs.

What Zepbound is approved for, and why it matters for prior authorization

Zepbound (tirzepatide) has two FDA-approved uses. According to the current prescribing information (revised August 2026), it is approved, alongside a reduced-calorie diet and more physical activity:

1. Chronic weight management: "to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition."
2. Obstructive sleep apnea: "to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity." The FDA approved this use on December 20, 2024. It was the first prescription medicine approved for OSA.

Plans usually write separate criteria for each use, and some plans cover one but not the other. The use your prescriber writes on the PA request decides which set of criteria applies.

The label also says taking Zepbound with other tirzepatide products or with any GLP-1 receptor agonist is not recommended. So if you already take Mounjaro or Ozempic, expect the plan to ask about it.

Typical criteria for weight management

The label's indication itself does not spell out BMI numbers, but plan criteria still do. They mirror the weight-management trials, which enrolled adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related condition.

A good example of real criteria is the CVS Caremark template policy for Zepbound (reference 6192-C). For weight management, it requires all of the following:

• Program participation: the patient "has participated in a comprehensive weight management program that encourages behavioral modification, reduced-calorie diet, AND increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy."
• BMI: a baseline BMI of 30 or more, or a baseline BMI of 27 or more with at least one weight-related condition (the policy's examples are hypertension, type 2 diabetes and dyslipidemia). Documentation is required.
• Diet and activity: the drug will be used with a reduced-calorie diet and more physical activity.

The word baseline matters. The CVS policy tells reviewers that if you are switching from another weight-loss drug, they should use your BMI from before you started any drug therapy. If you have already lost weight on a different GLP-1, your chart needs to show your starting BMI, not just your current one.

Other plans add their own requirements, such as trying cheaper drugs first. Our step therapy guide explains how those requirements work and what counts as "failure." Employer requirements vary widely. In KFF's 2025 Employer Health Benefits Survey, 34% of firms that cover GLP-1s for weight loss require enrollees to meet with a dietitian, case manager or therapist, or join a lifestyle program, to get coverage.

Typical criteria for obstructive sleep apnea

OSA criteria revolve around the sleep study. In the CVS Caremark template, a patient qualifies when:

• they have an established diagnosis of moderate to severe OSA, with an apnea-hypopnea index (AHI) of at least 15 events per hour on an in-lab sleep study (polysomnography) or a home sleep apnea test on a technically adequate device, and
• their current BMI is 30 or more.

Both require documentation. An AHI of 15 or more matches how the label's clinical studies defined moderate to severe OSA, and those trials enrolled patients with a BMI of 30 or more.

Some plans go further. UnitedHealthcare's commercial policy for Zepbound for OSA (program 2026 P 1475-3, effective September 1, 2026) requires, among other things:

• age 18 or older, with medical records showing a BMI of 30 or more and a sleep study with an AHI, REI or RDI above 15 events per hour;
• at least one previous unsuccessful dietary effort to lose weight;
• either continued OSA symptoms despite using PAP therapy consistently (defined as 4 or more hours a night on 70% or more of nights), or a reason the patient is not a candidate for PAP;
• no diagnosis of diabetes and an HbA1c no higher than 6.5%;
• prescriber confirmation that the patient was counseled on positional therapy and on avoiding alcohol or sedatives before bed, and that no surgery for sleep apnea or obesity is planned;
• no predominantly central or mixed sleep apnea;
• a prescriber who is a sleep medicine specialist, pulmonologist or ear, nose and throat specialist, or who works with one, or another physician experienced in managing OSA.

That list shows how much OSA criteria can differ between plans. The diabetes exclusion in that policy is one example; the policy does not explain it. Don't assume your plan follows either example. Ask for your own plan's policy.

For the medical side of sleep apnea and GLP-1s, see GLP-1s and sleep apnea.

How the sleep apnea approval changed coverage, including Medicare

Before December 2024, Zepbound had only a weight-management use, so a plan that excluded weight-loss drugs had nothing left to review. The OSA approval gave some of those plans a separate, medical reason to cover it.

Commercial plans. UnitedHealthcare's OSA policy says so plainly: "Medications for the purpose of weight loss are typically a benefit exclusion. The program allows for coverage of Zepbound for obesity with obstructive sleep apnea." Not every plan does this. Some employers exclude Zepbound for every use. The only way to know is to ask your plan whether Zepbound is covered for OSA, and to get the criteria in writing.

Medicare Part D. Federal law bars Part D from covering drugs used for weight loss, which is why Zepbound for weight management generally isn't covered (our Medicare GLP-1 coverage guide explains the background). OSA is a different, medically accepted use. CMS's current guidance on the Medicare GLP-1 Bridge (updated August 6, 2026) lists moderate to severe obstructive sleep apnea as one of the conditions that make a person ineligible for the Bridge, and says these conditions "qualify for Part D coverage instead." Lilly's coverage page likewise says Medicare coverage "can vary by condition."

In practice, this means:

• If you are on Medicare and have moderate to severe OSA with obesity, your Zepbound request goes to your Part D plan, under its formulary and PA rules. Whether your plan lists Zepbound, and on what tier, varies.
• If you are on Medicare and want Zepbound for weight management only, the separate Medicare GLP-1 Bridge may apply. CMS lists its dates as July 1, 2026 through December 31, 2027, with a $50 copay, and for Zepbound it covers only the KwikPen.

Why Zepbound prior authorizations get denied

The denial letter should give a reason. Most reasons fall into one of four groups, and each one calls for a different response.

1. Your plan excludes weight-loss drugs. Many plans don't cover drugs used for weight loss at all. In that case, no amount of paperwork will get a weight-management request approved. Coverage is still uneven. In KFF's 2025 survey, 16% of firms with 200 to 999 workers, 30% of firms with 1,000 to 4,999 workers and 43% of firms with 5,000 or more workers covered GLP-1s used mainly for weight loss. If you have OSA, ask whether the exclusion also applies to the OSA use. See does insurance cover GLP-1s for how to read your plan documents.

2. Your PBM prefers a different drug. Pharmacy benefit managers decide which drugs are "preferred" on their formularies. On July 1, 2025, CVS Caremark removed Zepbound from its standard commercial formularies and left Wegovy as the preferred GLP-1 for weight management. In May 2026, CVS Caremark announced it will add Zepbound back "as an additional preferred option October 1, 2026," while noting that employers using its template formularies "retain discretion to customize coverage." If a denial says a preferred alternative is available, your options are to try that drug or to ask for a formulary exception, with your prescriber explaining why the preferred drug isn't suitable for you. The CVS policy PDF also notes that Zepbound vials are handled through Lilly's own LillyDirect program rather than the pharmacy benefit.

3. A step or program requirement isn't documented. If your plan requires a supervised weight program, a trial of other medicines, or, for OSA, a PAP trial, the reviewer needs dated records showing it happened. Our step therapy guide covers this in detail.

4. Missing or mismatched documentation. Common problems include no dated BMI (or only a current BMI when the plan asks for baseline), a sleep study summary without the AHI value, a comorbidity mentioned in a note but not listed as a diagnosis, or a request filed under the weight-management criteria when the patient's strongest case is OSA. These denials are usually the easiest to fix, often by resubmitting a complete request.

What documentation helps

Reviewers check your records against a list. Before the request goes in, ask your prescriber's office to make sure the packet shows every item on your plan's list. Based on the published criteria above, that usually means:

For weight management

• Height, weight and BMI, with dates, including your baseline BMI from before any weight-loss medicine.
• Each weight-related condition listed as a diagnosis (for example, high blood pressure, type 2 diabetes, high cholesterol), not just mentioned in passing.
• Records of any required lifestyle or weight management program, with start dates and follow-up visits.
• Any required earlier medicines, with doses, dates and why each one was stopped.
• A note that Zepbound will be used with a reduced-calorie diet and more physical activity.

For obstructive sleep apnea

• The full sleep study report (in-lab or home test) showing the AHI (or REI/RDI) and the date of the study.
• Current BMI, dated.
• PAP history if your plan asks for it: usage data showing whether you used it consistently, or the medical reason you can't use it.
• The prescriber's specialty, or a note showing a sleep specialist was consulted, if the plan requires it.
• Any attestations the plan's form asks for, such as counseling on sleep position or alcohol.

For both, a short letter of medical necessity that names the FDA-approved use, points to the evidence for each criterion, and explains any special circumstances can help.

The most useful single step is getting your plan's actual criteria document. Call member services, or ask your prescriber's office to pull it. It is usually titled something like "Zepbound prior authorization" or "coverage criteria." Then check your records against it line by line.

How long prior authorization takes

Timelines depend on the type of plan:

• Medicare Part D: CMS requires plans to decide a standard coverage request within 72 hours and an expedited request within 24 hours. For an exception request (such as a drug not on the formulary), the clock starts once the plan has your prescriber's supporting statement.
• Employer plans governed by ERISA: federal claims rules allow up to 15 days for a non-urgent pre-service decision, with one possible extension of up to 15 more days, and no more than 72 hours for an urgent request.
• Fully insured and Marketplace plans: state law may set shorter deadlines. Your plan documents or state insurance department can tell you which rules apply.

In practice, the delay usually comes before the plan's clock starts: waiting for forms, chart notes or a sleep study report. If a request seems stuck, ask your prescriber's office whether it was submitted and whether the plan has asked for more information.

Renewals: what you need to show to stay approved

Approval is time-limited, and renewal is its own review. Plans want evidence the drug is working.

Weight management. In the CVS Caremark template, the first approval lasts 8 months, and renewals last 12 months. To renew, the patient must have "completed at least 3 months of therapy with the requested drug at a stable maintenance dose" and must have "lost at least 5 percent of baseline body weight OR... continued to maintain their initial 5 percent weight loss," with documentation.

Obstructive sleep apnea. In the CVS template, the first approval lasts 6 months and renewals last 12 months. Renewal needs the OSA diagnosis on file, a positive response "evidenced by a decrease in OSA symptoms," and treatment at a maintenance dose. UnitedHealthcare is stricter. For patients not on PAP, it asks for records showing a lower AHI (or REI/RDI) during the first year, and after 52 weeks, a 50% decrease from baseline. For patients who are on PAP, it asks for weight loss of at least 10% of baseline body weight. UnitedHealthcare renewals last 6 months during the first year and 12 months after that. The label's recommended maintenance dose for OSA is 10 mg or 15 mg weekly, which may matter if your plan's renewal criteria mention a maintenance dose.

What this means for you:

• Keep your baseline records. Your starting weight and your first sleep study are what renewals are measured against.
• Get weighed at visits. Weights recorded in your chart count. A number you mention to your doctor may not.
• Plan for a follow-up sleep study if your plan measures OSA response by AHI.
• Watch the expiry date. Ask your prescriber's office to submit the renewal a few weeks early so your refills aren't interrupted.

If your request is denied

Start with the denial letter. It should state the reason and your deadline to appeal. Then match the reason to your next step:

• Missing documentation: your prescriber can often resubmit or respond with the missing records.
• Preferred-drug or formulary denial: ask about a formulary exception, or discuss the preferred drug with your prescriber.
• Criteria not met: a peer-to-peer call between your prescriber and the plan's reviewer, or a formal appeal.
• Plan exclusion: an appeal rarely overturns a written benefit exclusion. If you have OSA, check whether the OSA use is treated differently.

Our GLP-1 prior authorization appeal guide covers internal appeals, peer-to-peer review, external review and letters of medical necessity step by step. If step therapy is the issue, see step therapy for Wegovy and Zepbound.

Paying cash while you wait

If you and your prescriber decide to start or continue Zepbound during a PA review or appeal, the main cash route is LillyDirect Self Pay. Lilly's coverage page lists the 2.5 mg KwikPen at $299 for a one-month supply. Higher doses cost more, and the lowest prices on doses of 7.5 mg and up require you to refill within 45 days of your last delivery. The self-pay offer is for cash patients only: you agree not to seek reimbursement from any insurer or government health program for fills bought with it.

• Prices by dose, the savings card for commercially insured patients and how it all compares: Zepbound cost.
• How to sign up: LillyDirect Zepbound enrollment walkthrough.

Whether to pay cash while a request is pending is a decision to make with your prescriber. Ask how starting on cash-pay might affect the "baseline" your plan uses later, and keep your records from before you started.

This article explains how insurance review generally works. It is not medical or legal advice. Your plan's own policy and your prescriber's judgment decide what applies to you.

Related coverage guides

• GLP-1 letter of medical necessity (with template)
• Wegovy prior authorization
• If your employer dropped GLP-1 coverage
• GLP-1 coverage by PBM (CVS Caremark, Express Scripts, Optum Rx)
• Ozempic and Mounjaro prior authorization for type 2 diabetes
• How to appeal a GLP-1 prior authorization denial
• Step therapy for Wegovy and Zepbound